<DOC>
	<DOCNO>NCT02532400</DOCNO>
	<brief_summary>To compare efficacy safety neoadjuvant aromatase inhibitor plus ovarian suppression chemotherapy premenopausal patient hormone receptor-positive breast cancer .</brief_summary>
	<brief_title>Neoadjuvant Aromatase Inhibitor ( AI ) With Ovarian Suppression Versus Chemotherapy Premenopausal Breast Cancer Patients</brief_title>
	<detailed_description>Neoadjuvant therapy nowadays standard treatment early stage locally advance breast cancer , exhibit similar benefit compare adjuvant therapy term disease free overall survival . Patients achieve pathological complete response ( pCR ) neoadjuvant chemotherapy superior outcome compare residual tumor breast and/or axilla . pCR wildly accept surrogate marker long-term survival patient , especially triple negative human epidermal growth factor receptor-2 ( HER2 ) -positive breast cancer . However , luminal HER2-negative breast cancer , neoadjuvant chemotherapy effective subtypes breast cancer , pCR less noted seem barely correlate long-term survival benefit . In postmenopausal patient hormone receptor-positive breast cancer , neoadjuvant endocrine therapy aromatase inhibitor achieve similar clinical response rate compare neoadjuvant chemotherapy , premenopausal hormone receptor-positive , HER2-negative breast cancer patient , neoadjuvant aromatase inhibitor plus ovarian function suppression ( OFS ) show pronounced efficacy tamoxifen plus OFS . In adjuvant setting , aromatase inhibitor combine OFS premenopausal patient hormone receptor-positive breast cancer demonstrate superior benefit term disease free survival , establish one routine option adjuvant endocrine therapy . Notwithstanding remarkable performance combination aromatase inhibitor OFS adjuvant therapy , role treatment strategy neoadjuvant setting yet prove compare neoadjuvant chemotherapy . The aim study prospectively compare efficacy safety neoadjuvant aromatase inhibitor plus OFS chemotherapy premenopausal patient hormone receptor-positive HER2-negative breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>1 . Written inform consent 2 . Women age ≥ 18 year 3 . Histologically confirm invasive breast cancer 4 . American Joint Committee Cancer ( AJCC ) stage : ⅡAⅢC , evidence metastasis 5 . At least one measurable disease breast and/or axilla 6 . ER and/or progesterone receptor ( PgR ) positive ( ≥10 % cell IHC ) 7 . HER2 negative ( IHC and/or FISH ) 8 . Premenopause status ( estradiol premenopausal range normal menstrual cycle past 6 month use hormonal drug ) 9 . Eastern Cooperative Oncology Group（ECOG）score 01 , estimate life expectancy least 12 month 10 . Adequate bone marrow function : Leukocyte ≥ 3.0*109/L ; Neutrophil ≥ 1.5*109/L ; Hb ≥ 100g/L ; Platelet ( PLT） ≥ 80*109/L 11 . Adequate liver , renal function coagulation function : Alanine transaminase（ALT） and/or Aspartate transaminase（AST）≤ 1.5 upper normal limit（UNL） , total bilirubin ≤upper normal limit , creatinine ≤ 110umol/L , Creatinine clearance &gt; 60ml/min , blood urea nitrogen（BUN） ≤ 7.1mmol/L , activate partial thromboplastin time（APTT） ≤ 1.5 upper normal limit（UNL） 12 . Women childbearing potential must negative pregnancy test ( urine serum ) within 7 day drug administration agree use acceptable method birth control avoid pregnancy duration study 13 . Serological record hepatitis B virus（HBV）and hepatitis C virus（HCV） test . 1 . Stage IV breast cancer 2 . Prior systemic locoregional treatment breast cancer 3 . Any antineoplastic treatment within 28 day begin study 4 . Known severe hypersensitivity drug study 5 . History malignancy within 5 year except carcinoma situ cervix skin basal cell carcinoma receive adequate treatment 6 . Peripheral neuropathy ≥ 2° , accord National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) ( Version 4.0 ) 7 . Any cardiac pulmonary dysfunction define follow : ( 1 ) ≥ 3° symptomatic congestive heart failure ( CHF ) accord NCI CTCAE ( Version 4.0 ) ≥ 2° CHF accord New York Heart Association（NYHA） ( 2 ) Angina need antianginal drug , advance conduction abnormality significant vascular disease ( 3 ) Uncontrolled highrisk arrhythmia : atrial tachycardia silent heart rate &gt; 100/min , significant ventricular arrythmia advance atrioventricular block ( 2° type II atrioventricular 3° atrioventricular block ) ( 4 ) Poorly control hypertension ( systolic BP &gt; 180 mmHg diastolic BP &gt; 100 mmHg ) ( 5 ) Transmural myocardial infarction EKG ( 6 ) Longterm oxygen therapy 8 . Uncontrolled severe systemic disease ( clinically significant cardiovascular disease，pulmonary disease metabolic disease , wound heal disorder , ulcer , severe infection ) 9 . Pregnant breast feed 10 . Major operation , obvious trauma within 28 day randomization plan major operation study 11 . Known active hepatic disease due hepatitis B virus , hepatitis C virus , autoimmune liver disease sclerosing cholangitis 12 . Known HIV infection 13 . Any reason investigator consider suitable study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Breast Neoplasms</keyword>
	<keyword>Neoadjuvant Endocrine Therapy</keyword>
	<keyword>Ovarian Function Suppression</keyword>
	<keyword>Neoadjuvant chemotherapy</keyword>
</DOC>